专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009056632A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
标题翻译：适用于治疗依托莫司汀5-HT6受体调节的病症的苯并呋喃半导体化合物
公开(公告)号：WO2009056632A1
公开(公告)日：2009-05-07
申请号：PCT/EP2008/064811
申请日：2008-10-31
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias , JONGEN-RELO, Ana Lucia , BESPALOV, Anton , ZHANG, Min
发明人： BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias , JONGEN-RELO, Ana Lucia , BESPALOV, Anton , ZHANG, Min
IPC分类号： C07D295/12 , C07D405/12 , A61K31/495 , A61K31/496 , A61P3/04 , A61P25/00 , A61P25/18 , A61P25/28 , A61P25/30
CPC分类号： C07D295/12 , C07D405/12
摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. wherein R 1 is hydrogen or methyl R 2 is hydrogen or methyl R 3 hydrogen, fluorine C 1 -C 2 alkoxy or fluorinated C 1 -C 2 alkoxy; R 4 is hydrogen, C 1 -C 4 alkyl or fluorinated C 1 -C 4 alkyl; R 5 is hydrogen, fluorine, C 1 -C 2 alkyl, fluorinated C 1 -C 2 alkyl, C 1 -C 2 alkoxy or fluorinated C 1 -C 2 alkoxy; and R 6 is hydrogen, fluorine or chlorine.
摘要翻译：本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。其中R1是氢或甲基R2是氢或甲基R3氢，氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基或氟化C1-C4烷基; R5是氢，氟，C1-C2烷基，氟化C1-C2烷基，C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯。

2. 发明申请

WO2008116831A1 QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
标题翻译：适用于治疗硒蓝蛋白5-HT6受体调节剂的喹啉化合物
公开(公告)号：WO2008116831A1
公开(公告)日：2008-10-02
申请号：PCT/EP2008/053387
申请日：2008-03-20
申请人： ABBOTT GMBH & CO. KG , TURNER, Sean Colm , HAUPT, Andreas , BRAJE, Wilfried , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias
发明人： TURNER, Sean Colm , HAUPT, Andreas , BRAJE, Wilfried , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , A61K31/4709 , A61P25/00
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. formula (I) wherein R is a moiety of the formula (R) wherein A, R 1 to R 4 are as defined in the claims and the specification, n is 0, 1 or 2; m is 0, 1, 2 or 3; R a , R b are independently selected from the group consisting of halogen, CN, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy, C(O)R aa , C(O)NR cc R bb and NR cc R bb ; X is CH 2 , C(O), S, S(O) or S(O) 2 ; which is located in the 3- or 4-position of the quinoline ring; Ar is a radical Ar 1 , Ar 2 -Ar 3 or Ar 2 -O-Ar 3 , wherein Ar 1 , Ar 2 and Ar 3 are each independently selected from the group consisting of aryl or hetaryl wherein aryl or hetaryl moieties may be unsubstituted or may carry 1, 2, 3 substituents R x , wherein and physiologically tolerated acid addition salts and the N-oxides thereof.
摘要翻译：本发明涉及新颖的喹啉化合物。该化合物具有有价值的治疗特性，特别适用于治疗对5-羟色胺5-HT 6受体调节作出反应的疾病。式（I）其中R是式（R）的部分，其中A，R 1至R 4如权利要求和说明书中所定义，n为0 ，1或2; m为0,1,2或3; R a，R b，R b各自独立地选自卤素，CN，C 1 -C 4 - - 烷基，C 1 -C 4 - 卤代烷基，C 1 -C 4 - 烷氧基，C

3. 发明申请

WO2009019286A1 QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
标题翻译：适用于治疗依托莫司汀5-HT6受体调节的病症的喹啉化合物
公开(公告)号：WO2009019286A1
公开(公告)日：2009-02-12
申请号：PCT/EP2008/060335
申请日：2008-08-06
申请人： ABBOTT GMBH & CO. KG , TURNER, Sean, Colm , BRAJE, Wilfried , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias
发明人： TURNER, Sean, Colm , BRAJE, Wilfried , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , WERNET, Wolfgang , MAYRER, Matthias
IPC分类号： C07D471/04 , C07D487/04 , C07D519/00 , A61K31/4709 , A61P35/00
CPC分类号： C07D487/04 , C07D471/04 , C07D519/00
摘要： The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R 1 , R 2 , R 3 , R 4 , R 5 , m, n, p, q, R a , R b , X and Ar are as defined in claim 1.
摘要翻译：本发明涉及式（I）的新颖喹啉化合物及其盐。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。在式（I）中，R是式（R）的部分，其中*表示与喹啉基的结合位点，其中A，B，X'，Y，Q，R 1，R 2，R 3，R 4，R 5， n，p，q，Ra，Rb，X和Ar如权利要求1所定义。

4. 发明申请

WO2009056600A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的苯并呋喃半导体化合物
公开(公告)号：WO2009056600A1
公开(公告)日：2009-05-07
申请号：PCT/EP2008/064732
申请日：2008-10-30
申请人： ABBOTT GMBH & CO. KG , TURNER, Sean Colm , HAUPT, Andreas , BRAJE, Wilfried , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
发明人： TURNER, Sean Colm , HAUPT, Andreas , BRAJE, Wilfried , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
IPC分类号： C07D213/76 , C07D401/04 , A61P25/00 , A61K31/444
CPC分类号： C07D401/04 , C07D213/76
摘要： The invention relates to compounds of the formula R 1 is selected from the group consisting of hydrogen, linear C 1 -C 3 alkyl and fluorinated linear C 1 -C 3 alkyl; R 2 is hydrogen or methyl; R 3 is selected from the group consisting of hydrogen, halogen, C 1 -C 2 -alkyl, fluorinated C 1 -C 2 -alkyl, C 1 -C 2 -alkoxy and fluorinated C 1 -C 2 -alkoxy, R 4 is C 1 -C 2 -alkyl or fluorinated C 1 -C 2 -alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
摘要翻译：本发明涉及式R1的化合物选自氢，直链C 1 -C 3烷基和氟化线性C 1 -C 3烷基; R2是氢或甲基; R3选自氢，卤素，C1-C2-烷基，氟化C1-C2-烷基，C1-C2-烷氧基和氟化C1-C2-烷氧基，R4是C1-C2-烷基或氟化C1-C2 -烷基; n为0,1或2，以及这些化合物的生理上耐受的盐及其N-氧化物。本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

5. 发明申请

WO2009056625A1 1,2,4,-TRIAZIN-3,5-DIONE COMPOUNDS FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： 1,2,4，-TRIAZIN-3,5-Dipone化合物，用于治疗多巴胺D3受体调节症状
公开(公告)号：WO2009056625A1
公开(公告)日：2009-05-07
申请号：PCT/EP2008/064795
申请日：2008-10-31
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , GENESTE, Hervé , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
发明人： BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , GENESTE, Hervé , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
IPC分类号： C07D403/12 , A61K31/53 , A61P25/00 , A61P25/18 , A61P25/30
CPC分类号： C07D403/12
摘要： The invention relates to compounds of the formula (I), wherein A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R 1 is selected from the group consisting of hydrogen, C 1 -C 3 alkyl and fluorinated C 1 -C 3 alkyl; R 2 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, fluorinated C 1 -C 3 alkyl or fluorinated C 1 -C 3 alkoxy; R 3 is selected from the group consisting of branched C 4 -C 6 alkyl and C 3 -C 6 cycloalkyl, and R 4 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 3 alkyl and fluorinated C 3 -C 6 cycloalkyl. and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and furtherto amethod for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
摘要翻译：本发明涉及式（I）化合物，其中A是链长为4-6个碳原子的饱和或不饱和烃链，该烃链未被取代或被1,2或3个甲基取代; R1选自氢，C1-C3烷基和氟化C1-C3烷基; R2是氢，卤素，氰基，C1-C3烷基，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R3选自支链C 4 -C 6烷基和C 3 -C 6环烷基，且R 4为C 1 -C 6烷基，C 3 -C 6环烷基，氟化C 1 -C 3烷基和氟化C 3 -C 6环烷基。以及这些化合物的生理上耐受的盐及其N-氧化物。本发明还涉及包含至少一种式（I）化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及用于治疗有益于多巴胺D3受体拮抗剂或多巴胺D3拮抗剂的病症的方法，所述方法包括向有需要的受试者施用有效量的至少一种式（I）的化合物或生理学上耐受的酸加成盐。

6. 发明申请

WO2008116833A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
标题翻译：适用于治疗响应调节SEROTONIN 5-HT6受体的疾病的AZETIDIN化合物
公开(公告)号：WO2008116833A1
公开(公告)日：2008-10-02
申请号：PCT/EP2008/053389
申请日：2008-03-20
申请人： ABBOTT GMBH & CO. KG , SCHULTZ, Thomas , BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , MAYRER, Matthias
发明人： SCHULTZ, Thomas , BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , MEZLER, Mario , MAYRER, Matthias
IPC分类号： C07D403/04 , C07D471/04 , A61K31/404 , A61P25/28
CPC分类号： C07D471/04 , C07D403/04
摘要： The present invention relates to compounds of formula (I) wherein A is C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -hydroxyalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -haloalkenyl, C 3 -C 6 -cycloalkyl, aryl-C 1 -C 4 -alkyl, aryl-C 2 -C 4 -alkenyl, aryl or hetaryl; --- is a single or double bond; X 1 and X 2 are N, CR x1 , NR x2 or CR x3 R x4 ; R x1 , R x3 and R x4 are H, halogen, CN, NO 2 , C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylcarbonyl, etc. or two geminal radicals R x3 and R x4 together with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro- annulated ring; R x2 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkylcarbonyl, C 1 -C 6 -haloalkyl, etc.; or two vicinal radicals R x1 , R x2 , R x3 or R x4 together with X 1 and X 2 form a five- or six- membered carbocyclic or heterocyclic fused ring; Y 1 , Y 2 and Y 3 are N or CR y ; R y is H, halogen, CN, NO 2 , C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylcarbonyl, C 1 -C 6 -haloalkyl, etc.; wherein a maximum of 3 of the radicals X 1 , X 2 , Y 1 , Y 2 and Y 3 are selected from NR x1 and N; R 1 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -haloalkyl, etc.; R 2 is C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.
摘要翻译：本发明涉及式（I）的化合物，其中A是C 1 -C 6 - 烷基，C 1 -C 3 - 6个 - 卤代烷基，C 1 -C 6 - 羟基烷基，C 2 -C 6 - 烯基，C 2 -C 6 - 卤代烯基，C 3 -C 6 - 环烷基，芳基-C 芳基-C 2 -C 4 - 亚烷基，芳基或杂芳基; C 1 -C 4烷基，C 1 -C 4烷基， ---是单键或双键; X 1和X 2是N，CR 1，X 2，X 2或CR 3 x 3 > - [R ^{X4 ; R 1，X 3和R 4是H，卤素，CN，NO 2，C 1， C 1 -C 6 - 烷基，C 1 -C 6 - 烷氧基，C 1 -C 6 - 烷基，C 1 -C 6 - C 6 - 烷基羰基等，或两个偕根基R 3和R 4以及它们所结合的碳原子一起形成羰基或3-至6-元碳环或杂环螺环环; R 2是氢，C 1 -C 6 - 烷基，C 1 -C 6 - C 1 -C 6烷基羰基，C 1 -C 6 - 卤代烷基等; 或两个邻位基团X 1，X 2，R x 3或R x 4，以及X 1 ＆lt;和＆lt; 2＆gt;和＆lt; 2＆gt;形成五元或六元碳环或杂环稠环; Y 1，Y 2和Y 3是N或CR y; R 1是H，卤素，CN，NO 2，C 1 -C 6 - 烷基，C 1 -C 6烷基， C 1 -C 6 - 烷氧基，C 1 -C 6 - 烷基羰基，C 1〜 -C 6 -C 6 - 卤代烷基等; 其中基团X 1，X 2，Y 1，Y 2和Y 2中的最多3个， SUP> 3 选自NRIX和N; R 1是氢，C 1 -C 6 - 烷基，C 1 -C 6 - 烷基，C 1 -C 6 - 羟基烷基，C 1 -C 6 - 卤代烷基等; R 2是C 1 -C 4 - 烷基或C 1 -C 4 - / - > - 卤代烷基; n为0,1或2; 生理耐受的酸加成盐及其N-氧化物，包含它们的药物组合物，治疗选自中枢神经系统疾病，成瘾疾病或肥胖症的医学病症的方法，所述方法包括向受试者施用有效量的这些化合物并且使用这种化合物来制备药物组合物。}

7. 发明申请

WO2006015842A1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的4-哌啶子基吡啶化合物
公开(公告)号：WO2006015842A1
公开(公告)日：2006-02-16
申请号：PCT/EP2005/008592
申请日：2005-08-08
申请人： ABBOTT GMBH & CO. KG , HAUPT, Andreas , UNGER, Liliane , DRESCHER, Karla , JONGEN-RELO, Ana, Lucia , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé
发明人： HAUPT, Andreas , UNGER, Liliane , DRESCHER, Karla , JONGEN-RELO, Ana, Lucia , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé
IPC分类号： C07D417/12
CPC分类号： C07D239/42 , C07D239/52 , C07D239/56 , C07D401/12 , C07D403/12 , C07D417/12
摘要： The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D 3 receptor. The 4 piperzinylpyrimidine compounds have the general formula (I), wherein Ar, X, A, R 1 and R 1a are as defined in the claims.
摘要翻译：本发明涉及新的4-哌嗪基嘧啶化合物。该化合物具有有价值的治疗性质，特别适用于治疗对多巴胺D 3受体调节作出反应的疾病。 4个哌嗪基嘧啶化合物具有通式（I），其中Ar，X，A，R 1和R 1a如权利要求中所定义。

8. 发明申请

WO2007118899A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR 审中-公开
标题翻译：用于治疗反应调节SEROTONIN 5HT6受体的疾病的异环芳烃
公开(公告)号：WO2007118899A1
公开(公告)日：2007-10-25
申请号：PCT/EP2007/053807
申请日：2007-04-18
申请人： ABBOTT GMBH & CO. KG , GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , PLATA, Dan
发明人： GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , PLATA, Dan
IPC分类号： C07D205/04 , C07D207/09 , C07D211/28 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/445 , A61K31/397 , A61K31/4025 , A61P25/18
CPC分类号： C07D207/09 , C07D205/04 , C07D211/28 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要： The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中变量具有权利要求书和说明书中给出的含义。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受5HT 6受体配体治疗的医学疾病的药物中的用途。

9. 发明申请

WO2007118900A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR 审中-公开
标题翻译：用于治疗响应调节SEROTONIN 5HT6受体的疾病的异种化合物
公开(公告)号：WO2007118900A1
公开(公告)日：2007-10-25
申请号：PCT/EP2007/053808
申请日：2007-04-18
申请人： ABBOTT GMBH & CO. KG , GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
发明人： GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , A61K31/4545 , A61P25/00
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中变量具有权利要求书和说明书中给出的含义。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受5HT 6受体配体治疗的医学疾病的药物中的用途。

10. 发明申请

WO2007118859A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节症状的ARYLOXYYHYLAMINE化合物
公开(公告)号：WO2007118859A1
公开(公告)日：2007-10-25
申请号：PCT/EP2007/053633
申请日：2007-04-13
申请人： ABBOTT GMBH & CO. KG , GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
发明人： GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
IPC分类号： C07D213/76 , C07D239/69 , A61K31/4439 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/28
CPC分类号： C07D213/76 , C07D239/69
摘要： The present invention relates to aryloxyethylamine compounds of the formula (I) and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳氧基乙胺化合物及其生理上耐受的酸加成盐。变量具有权利要求书和说明书中给出的含义。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式